Cargando…
SampPick: Selection of a Cohort of Subjects Matching a Population HLA Distribution
Immune responses to therapeutic proteins and peptides can adversely affect their safety and efficacy; consequently, immunogenicity risk-assessments are part of the development, licensure and clinical use of these products. In most cases the development of anti-drug antibodies is mediated by T cells...
Autores principales: | McGill, Joseph R., Yogurtcu, Osman N., Verthelyi, Daniela, Yang, Hong, Sauna, Zuben E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933600/ https://www.ncbi.nlm.nih.gov/pubmed/31921155 http://dx.doi.org/10.3389/fimmu.2019.02894 |
Ejemplares similares
-
Mathematical model of a personalized neoantigen cancer vaccine and the human immune system
por: Rodriguez Messan, Marisabel, et al.
Publicado: (2021) -
HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset
por: McGill, Joseph R., et al.
Publicado: (2021) -
A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII
por: Rawal, Atul, et al.
Publicado: (2023) -
Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023) -
Editorial: Immunogenicity of Proteins Used as Therapeutics
por: Sauna, Zuben E., et al.
Publicado: (2020)